Zydus specialty products reach 16% of US sales in Q2 FY27

In Q2 FY27, Zydus Lifesciences Limited said specialty products accounted for 16% of US revenue, approximately 550 basis points higher sequentially. The increase followed the prior-quarter acquisition of Assertio Holdings and addition of Rolvedon, while North America revenue, including the US and Canada, rose 21% year on year to Rs 3,310 crore.

What drove Zydus's specialty mix higher in Q2 FY27?

Zydus said the specialty mix rose because Rolvedon was added following the Assertio acquisition in the prior quarter and its 505(b)(2) portfolio maintained traction. Specialty products represented 16% of US revenue in Q2 FY27, an increase of approximately 550 basis points from the preceding quarter. Management described the US specialty business as delivering strong sequential growth.

The disclosure measures specialty as a share of US revenue, not of the wider North America business. Zydus reported Rs 3,310 crore of North America revenue in Q2 FY27, including the US and Canada, but did not disclose standalone US revenue, specialty sales in rupees, or Rolvedon revenue. The reported percentage therefore shows a business-mix change without quantifying the absolute size of specialty sales.

Rolvedon was the acquisition-related product specifically named as contributing to the shift. Management also identified differentiated 505(b)(2) products, rare-disease offerings and a biologics pipeline as US growth vectors, although the November 4, 2026 call gave no sales split among those products or platforms.

How did Zydus's North America revenue compare with other businesses?

Zydus's North America business generated Rs 3,310 crore in Q2 FY27, up 21% year on year and 7% quarter on quarter. Management attributed the increase to sustained volume expansion in the base generics business and continued scale-up of the US specialty operation. The 16% specialty figure applies only to US revenue and should not be applied to the reported North America total.

International markets formulations generated Rs 1,000 crore in Q2 FY27, up 33% year on year, a faster stated growth rate than North America's 21%. Consumer wellness reported Rs 1,120 crore, up 76% year on year, while medical devices reported Rs 220 crore. North America was larger by revenue than each of those separately disclosed businesses despite consumer wellness recording the highest year-on-year growth rate.

Zydus reported consolidated revenue of Rs 7,910 crore in Q2 FY27, up 29% year on year. This puts the North America figure in the context of company-wide growth, but the transcript does not provide a reconciliation between North America revenue and the 16% US specialty contribution.

What US launches and filings supported Zydus's portfolio?

Zydus supported its US generics franchise with four abbreviated new drug application filings, 12 approvals and five product launches in Q2 FY27. An abbreviated new drug application is the US regulatory filing route for a generic medicine. In October 2026, Zydus launched the first generic version of Riociguat tablets.

Management said the Riociguat launch had started well and that both specialty distributors in that market were working with Zydus. It said the company had gained good share with the two distributors and hoped to secure market share, but did not provide prescriptions, inventory, sales or a revenue forecast for the product.

Rolvedon continued to gain momentum, according to management, as part of the specialty portfolio that lifted the mix to 16% of US revenue. The company also said the US Food and Drug Administration had accepted for review a biologics license application for a Pembrolizumab biosimilar developed by partner Formycon. Management called this the first publicly announced Keytruda biosimilar filing accepted for review in the US, without providing a review decision date.

How does specialty expansion support Zydus's branded-business target?

Zydus said specialty expansion is part of its effort to reshape the US business beyond generics toward specialty and biologics. Branded businesses represented around 57% of consolidated revenue in Q2 FY27, up 150 basis points from the prior quarter. Management's medium-term aspiration is for branded businesses to account for two-thirds of consolidated revenue.

India-branded formulations grew 19% year on year in Q2 FY27 and 20% in H1 FY27. Zydus said chronic and sub-chronic products made up 56.9% of its India portfolio in the 12 months ended September 2026, up 450 basis points over four years. That domestic mix development is separate from the 16% US specialty measure, but both disclosures reflect management's stated focus on branded and differentiated portfolios.

The company reported earnings before interest, tax, depreciation and amortisation, or EBITDA, of Rs 1,890 crore in Q2 FY27, with a 24% margin. Management said the margin would have been 150 basis points higher excluding Saroglitazar launch-related investment. Net profit was Rs 930 crore, and net debt to EBITDA stood at 0.62 times at September 30, 2026.

What specialty assets could add to Zydus's US platform?

Zydus's wholly owned US subsidiary, Sentynl Therapeutics, entered a licensing agreement with Mereo Biopharma during Q2 FY27 for Alvelestat. The asset was being prepared for Phase III development for Alpha-1 Antitrypsin Deficiency Associated Lung Disease, a rare genetic respiratory disorder. Management said Alvelestat has the potential to become the first oral treatment for the condition, not that it has been approved or launched.

Saroglitazar is another planned US commercial initiative. Management said on November 4, 2026 that it had continued investing in commercialisation from the previous quarter and expected investment to rise over the next two quarters. It said it had answered regulatory queries received so far and was working toward a March launch, while noting that November was the current goal date and that further late queries could affect timing.

Zydus also reported that a Phase II(b) trial of Saroglitazar magnesium in metabolic dysfunction-associated steatohepatitis met its primary endpoint at 52 weeks. Separately, it presented Phase III analysis in primary biliary cholangitis at the American College of Gastroenterology 2026 annual meeting. These clinical updates concern development programmes and do not establish US commercial revenue.

Conclusion

Zydus's 16% specialty contribution to US revenue in Q2 FY27, up approximately 550 basis points sequentially, provides a direct indicator of a changing US business mix. Rolvedon's addition after the Assertio acquisition was the stated immediate driver, alongside traction in 505(b)(2) products, while North America revenue increased 21% year on year to Rs 3,310 crore.

The next disclosures to watch are whether the specialty share changes after the acquisition comparison matures and whether North America maintains growth beyond the reported 7% quarter-on-quarter increase. Management's planned March Saroglitazar launch, subject to the regulatory process, continued US commercial investment over the next two quarters, and the US Food and Drug Administration review of the Pembrolizumab biosimilar application are the stated upcoming milestones.